Global  

India trials for Russia's 'Sputnik-V' vaccine could start in next few weeks: Dr Reddy's

IndiaTimes Tuesday, 22 September 2020
Dr Reddy's Laboratories Ltd could begin late-stage Indian clinical trials of Russia's potential coronavirus vaccine in the next few weeks, an executive at the Indian drugmaker said on Tuesday.
0
shares
ShareTweetSavePostSend
 
Video Credit: In The Know Wibbitz - Published
News video: Why you need to pay attention to the fall equinox this year

Why you need to pay attention to the fall equinox this year 00:56

The Earth will experience its second equinox of the year on September 22 — marking the first official day of fall.During its two annual equinoxes, the Earth, will be perpendicular to the sun’s rays and will create a moment where night and day are almost exactly equal.Over the next few weeks,...

You Might Like


💡 One News Page Knowledge: Other News Mentions

Gam-COVID-Vac Gam-COVID-Vac Viral vector vaccine candidate based on human adenovirus

Russian Sputnik V Covid-19 vaccine to be tested on 100 Indian volunteers

The Russian Sputnik V vaccine against Covid-19 will be tested in India on 100 volunteers, the Indian Central Drugs Standard Control Organisation's Drug..
IndiaTimes
Covid-19 cases dip, PM Modi calls for ‘speedy delivery’ of vaccines [Video]

Covid-19 cases dip, PM Modi calls for ‘speedy delivery’ of vaccines

As coronavirus infections continue to dip for the third consecutive week, Prime Minister Narendra Modi on Saturday called for a speedy delivery of Covid-19 vaccine once they are developed. Charing a high-level meet, the PM called for using the election infrastructure of the country for the speedy delivery of the vaccines. His remarks come on day the country’s drug controller allowed clinical trials of Russia’s Sputnik V vaccine candidate and the Serum Institute of India, which is to manufacture the Oxford vaccine candidate, said that India may get a Covid-19 vaccine by March next year. Top stories in this editorji evening playlist.

Credit: HT Digital Content    Duration: 05:47Published

Dr Reddy's gets DCGI go-ahead to conduct Phase 2/3 human trials of Sputnik V in India

After the Indian drug regulator turned down Dr. Reddy’s Laboratories Ltd’s proposal earlier this month to conduct direct Phase-3 human trials for the Russian..
IndiaTimes
Covid update: N95 mask export allowed; India ranks 4th; festival guidelines [Video]

Covid update: N95 mask export allowed; India ranks 4th; festival guidelines

From the Union government lifting restrictions on the export of N-95/FFP2 face masks, to India ranking fourth in a survey of public perception regarding response to the pandemic - here are the top news updates on the Covid-19 outbreak. The central government released guidelines for gatherings as festival season approaches. The standard operating procedure involves mandatory use of masks, social distancing and CCTVs at event sites to monitor compliance. Event premises are also expected to have isolation rooms in case an infected person is found. The Drugs Controller General of India has asked Dr Reddy's Laboratories to file a revised protocol to conduct Phase 2 and 3 clinical trials of Russian vaccine Sputnik V in the country. Meanwhile, the International Monetary Fund said that the economic downturn caused by the pandemic was not as bad as originally feared, thanks to government spending measures. Watch the full video for the other updates regarding the spread of the Sars-CoV-2 coronavirus.

Credit: HT Digital Content    Duration: 03:14Published

Dr. Reddy's Laboratories Indian multinational pharmaceutical company

Opening Bell: Equity indices in the red amid weak global cues [Video]

Opening Bell: Equity indices in the red amid weak global cues

Equity benchmark indices were down on September 30. At 10:00 am, the BSE was down by 95 points or 0.25 per cent and was trading at 37,876, while Nifty was trading also dipped by 7 points or -0.06 per cent at 11,215. The top gainers in the BSE include Sun Pharma, HUL and Asian Paints. SunPharma was trading up with shares at Rs 512 points up by 1.57 per cent, HUL was at Rs 2,055 and Asian Paints at Rs 1,979. Top gainers at NSE included CIPLA, Dr Reddy and Divi's Laboratories Limited. CIPLA was trading at Rs 789 up by 3.49 per cent, Dr Reddy at Rs 5,225 up by 2.77 per cent and Divi's Laboratories Limited was trading at Rs 3,119.

Credit: ANI    Duration: 01:10Published

Related videos from verified sources

Brazil vaccine participant dies: What next for trials? | Oneindia News [Video]

Brazil vaccine participant dies: What next for trials? | Oneindia News

A vaccine trial participant for Astrazeneca's Covid-19 candidate vaccine has died in Brazil, but the trials won't stop. Some reports say that the person who died had not received the vaccine shot yet...

Credit: Oneindia     Duration: 01:19Published
'Vaccine trials are being expedited,' says Harsh Vardhan at World Bank Annual Meetings [Video]

'Vaccine trials are being expedited,' says Harsh Vardhan at World Bank Annual Meetings

Health Minister Dr Harsh Vardhan at World Bank Annual Meetings Virtual Event said the private companies with research institutes are expediting trials of vaccine candidates. "To address present and..

Credit: ANI     Duration: 02:10Published
'Covid-19 vaccine expected in India by early 2021': Harsh Vardhan [Video]

'Covid-19 vaccine expected in India by early 2021': Harsh Vardhan

Union Health Minister Harsh Vardhan said that India is likely to have a Covid vaccine by early next year. Harsh Vardhan made the statement in a meeting of the Group of Ministers (GoM). "Early next year..

Credit: HT Digital Content     Duration: 04:05Published

Related news from verified sources

India trials for Russia's 'Sputnik-V' vaccine could start in next few weeks: Dr Reddy's

Dr Reddy's Laboratories Ltd could begin late-stage Indian clinical trials of Russia's potential coronavirus vaccine in the next few weeks, an executive at the...
IndiaTimes Also reported by •DNA

Russia to sell 100 million doses of Covid-19 vaccine to India

Russia's sovereign wealth fund said on Wednesday it will supply India's Dr Reddy's Laboratories with 100 million doses of the Sputnik-V vaccine against Covid-19...
IndiaTimes

Russia, Dr Reddy’s tie up for Sputnik V trial

Russia’s sovereign wealth fund – Russian Direct Investment Fund (RDIF) — has partnered Hyderabad-based drug maker Dr Reddy’s Laboratories to cooperate on...
IndiaTimes


Tweets about this